Scarica l'app Stockscreener
1.98
1.02%
0.02
Dopo l'orario di chiusura:
2.05
0.07
+3.54%
Precedente Chiudi:
$1.96
Aprire:
$1.85
Volume 24 ore:
230.56K
Relative Volume:
0.21
Capitalizzazione di mercato:
$5.84M
Reddito:
-
Utile/perdita netta:
$-15.47M
Rapporto P/E:
-3.96
EPS:
-0.5
Flusso di cassa netto:
$-13.51M
1 W Prestazione:
+6.45%
1M Prestazione:
-27.21%
6M Prestazione:
-79.55%
1 anno Prestazione:
-89.69%
Intervallo 1D:
$1.85
$2.019
Intervallo di 1 settimana:
$1.71
$2.06
Portata 52W:
$1.71
$20.80
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Nome
Nls Pharmaceutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NLSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
1.98 | 5.84M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nls Pharmaceutics Ltd Borsa (NLSP) Ultime notizie
NLS Pharmaceutics Submits Research Abstracts to ASCP 2025 - TipRanks
NLS Pharmaceutics Launches Preclinical Program for Fentanyl Dependence Treatment - TipRanks
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Marketscreener.com
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence - Benzinga
NLSP Stock Touches 52-Week Low at $1.73 Amid Steep Annual Decline - MSN
NLS Pharmaceutics and Kadimastem Announce Initial Closing of $500,000 Fundraising Effort for Merger - HPBL
NLS Pharmaceutics and Kadimastem Move Forward with Merger to Create Nasdaq-Traded Biotechnology Company - HPBL
NLS Pharmaceutics and Kadimastem Merger & Financing Update – Market - HPBL
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS - The Malaysian Reserve
Kadimastem Calls for a Special General Meeting of Shareholders t - GuruFocus.com
NLS Pharmaceutics and Kadimastem Move Toward Merger Approval - TipRanks
NLS Pharmaceutics Completes Initial $500K Financing to Advance Kadimastem Merger - Sleep Review
NLS Pharmaceutics and Kadimastem Advance Merger Plans with $500,000 Fundraising - Yahoo Finance
NLS Pharmaceutics Announces Extraordinary Shareholders’ Meeting Results – Market - HPBL
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market S - The Malaysian Reserve
NLS Pharmaceutics Secures Premium-Priced $500K Investment, Advances Kadimastem Merger Plans - StockTitan
Head-To-Head Analysis: Atossa Therapeutics (NASDAQ:ATOS) & NLS Pharmaceutics (NASDAQ:NLSP) - Defense World
NLS Pharmaceutics Shareholders Approve Meeting Agenda - TipRanks
Merger Between NLS Pharmaceutics and Kadimastem Advances with SEC Filing - Sleep Review
What's Going On With NLS Pharmaceuticals Stock Monday? - Benzinga
NLS Pharmaceutics and Kadimastem Move Forward with Merger Plans - TipRanks
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger - IT News Online
NLS Pharmaceutics and Kadimastem Advance Merger Plans with SEC Registration for CNS Drug Development - StockTitan
NLS Pharmaceutics Calls Extraordinary Meeting for Major Capital Restructuring - TipRanks
NLS Pharmaceutics and Kadimastem eye January merger - Investing.com
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - AccessWire
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline By Investing.com - Investing.com South Africa
NLS Pharmaceutics Advances Revolutionary Type 1 Diabetes Treatment, Seeks FDA Pre-IND Meeting - StockTitan
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline - Investing.com India
NLS Pharmaceutics expects to close Kadimastem merger by end of January - Yahoo Finance
NLSP stock touches 52-week low at $1.81 amid market challenges - Investing.com Nigeria
NLS Pharmaceutics advances in narcolepsy treatment research By Investing.com - Investing.com Nigeria
NLS CEO Highlights Progress on Dual Orexin Agonist Platform and Upcoming Merger - Sleep Review
NLS Pharmaceutics Advances DOXA Platform Amid Merger Plans - TipRanks
NLS Pharmaceutics advances in narcolepsy treatment research - Investing.com India
NLS Pharmaceutics CEO Issues Letter to Shareholders - AccessWire
NLS Pharmaceutics Secures $4.2M Funding, Reports Breakthrough in Narcolepsy Treatment Development - StockTitan
NLS Pharmaceutics AG announced that it expects to receive $0.999998 million in funding - Marketscreener.com
Nls Pharmaceutics Ltd Azioni (NLSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):